Analyst: Ebola order has positive signal value for Bavarian's investors

The recent USD 28m order that Janssen has placed with Bavarian hints at the fact that ebola outbreaks will keep occurring in the future, according to Danish bank analyst Søren Løntoft Hansen.

Photo: Sydbank/PR

The new bulk vaccine order placed with Bavarian Nordic for the ebola vaccine to which Johnson & Johnson holds the rights has positive signal value for investors, according to Senior Equity Analyst Søren Løntoft Hansen from the Danish bank Sydbank, following Bavarian Nordic's Tuesday announcement that the order amounted to USD 28m.

The Ebola vaccine was recommended for approval by the EU in May 2020 and finally approved in 2020. And in June 2020, already, Bavarian received an order worth USD 13.9m from Johnson & Johnson to produce and supply the ebola vaccine in bulk vaccines.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs